New hope for Hard-to-Treat cancers: enhertu studied in 20+ tumor types
NCT ID NCT07124000
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and for how long. The study covers many cancer types, such as bladder, cervical, ovarian, and pancreatic cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab deruxtecan (Enhertu)
What this could lead to
If successful, this could show that T-DXd is an effective treatment option for many types of HER2-positive cancers that have stopped responding to other therapies.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. The drug may not work for all tumor types, and side effects like lung inflammation are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBirmingham, Alabama, 35243, United States
-
Research Site
RECRUITINGBullhead City, Arizona, 86442, United States
-
Research Site
RECRUITINGCasa Grande, Arizona, 85122, United States
-
Research Site
RECRUITINGSan Diego, California, 92123, United States
-
Research Site
RECRUITINGBoulder, Colorado, 80309, United States
-
Research Site
RECRUITINGCoral Springs, Florida, 33065, United States
-
Research Site
RECRUITINGSt. Petersburg, Florida, 33714, United States
-
Research Site
RECRUITINGWest Palm Beach, Florida, 33401, United States
-
Research Site
RECRUITINGDecatur, Illinois, 62526, United States
-
Research Site
RECRUITINGTopeka, Kansas, 66604, United States
-
Research Site
RECRUITINGDurham, North Carolina, 27708, United States
-
Research Site
RECRUITINGWilson, North Carolina, 27893, United States
-
Research Site
RECRUITINGCanton, Ohio, 44718, United States
-
Research Site
RECRUITINGMaumee, Ohio, 43537, United States
-
Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Research Site
RECRUITINGNashville, Tennessee, 37203, United States
-
Research Site
RECRUITINGDallas, Texas, 75390, United States